PerrosP, HegedusL, NagyEV, et al.The impact of hypothyroidism on satisfaction with care and treatment and everyday living: Results from E-mode patient self-assessment of thyroid therapy, a cross-sectional, international online patient survey. Thyroid, 2022; 32(10):1158–1168; doi: 10.1089/thy.2022.0324
2.
PerrosP, NagyEV, PapiniE, et al.Hypothyroidism and somatization: Results from E-mode patient self-assessment of thyroid therapy, a cross-sectional, international online patient survey. Thyroid, 2023; 33(8):927–939; doi: 10.1089/thy.2022.0641
3.
HaladaS, BaranJA, IsazaA, et al.Impact of definitive surgery for Graves' disease on adolescent disease-specific quality of life and psychosocial functioning. Thyroid, 2022; 32(12):1519–1528; doi: 10.1089/thy.2022.0334
4.
ZiaiH, DixonP, BermanG, et al.Incidental parathyroidectomy among pediatric patients undergoing thyroid surgery. Laryngoscope, 2022; 132(11):2262–2269; doi: 10.1002/lary.30056
5.
BarrancoH, FazendinJ, LindemanB, et al.Thyroid hormone replacement following lobectomy: Long-term institutional analysis 15 years after surgery. Surgery, 2023; 173(1):189–192; doi: 10.1016/j.surg.2022.05.044
6.
LopezB, FligorSC, RandolphGW, et al.Inequities in thyroid cancer care: Populations most at risk for delays in diagnosis and treatment. Thyroid, 2023; 33(6):724–731; doi: 10.1089/thy.2022.0723
7.
LuffMK, KimJ, TsengCH, et al.Racial/ethnic disparities in thyroid cancer in California, 1999–2017. Am J Surg, 2023; 225(2):298–303; doi: 10.1016/j.amjsurg.2022.09.041
8.
SharmaRK, PatelS, GallantJN, et al.Racial, ethnic, and socioeconomic disparities in the presentation and management of pediatric thyroid cancer. Int J Pediatr Otorhinolaryngol, 2022; 162:111331; doi: 10.1016/j.ijporl.2022.111331
9.
GinzbergSP, Soegaard BallesterJM, WirtallaCJ, et al.Racial and ethnic disparities in appropriate thyroid cancer treatment, before and after the release of the 2015 American Thyroid Association Guidelines. Ann Surg Oncol, 2023; 30(5):2928–2937; doi: 10.1245/s10434-023-13158-3
10.
GinzbergSP, Soegaard BallesterJM, WirtallaCJ, et al.Insurance-based disparities in guideline-concordant thyroid cancer care in the era of de-escalation. J Surg Res, 2023; 289:211–219; doi: 10.1016/j.jss.2023.03.046
11.
ZhuoH, HuangH, SjodinA, et al.A nested case-control study of serum polychlorinated biphenyls and papillary thyroid cancer risk among U.S. military service members. Environ Res, 2022; 212(Pt C):113367; doi: 10.1016/j.envres.2022.113367
12.
TongWJ, WuSH, ChengMQ, et al.Integration of artificial intelligence decision aids to reduce workload and enhance efficiency in thyroid nodule management. JAMA Netw Open, 2023; 6(5):e2313674; doi: 10.1001/jamanetworkopen.2023.13674
13.
AziziF, AbdiH, MehranL, et al.Long-term follow-up of graves orbitopathy after treatment with short- or long-term methimazole or radioactive iodine. Endocr Pract, 2023; 29(4):240–246; doi: 10.1016/j.eprac.2023.01.006
14.
GillS, CheedV, MortonVAH, et al.Evaluating the progression to hypothyroidism in preconception euthyroid thyroid peroxidase antibody-positive women. J Clin Endocrinol Metab, 2022; 108(1):124–134; doi: 10.1210/clinem/dgac525
15.
ChortiA, BontinisV, TzikosG, et al.Minimally invasive treatments of benign thyroid nodules: A network meta-analysis of short-term outcomes. Thyroid, 2023; 33(8):950–964; doi: 10.1089/thy.2022.0671
16.
XiangP, AhmadiS, ColemanA, et al.Identifying and predicting diverse patterns of benign nodule growth. J Clin Endocrinol Metab, 2023; 108(7):e458–e463; doi: 10.1210/clinem/dgad007
17.
LiuJB, BaughKA, RamonellKM, et al.Molecular testing predicts incomplete response to initial therapy in differentiated thyroid carcinoma without lateral neck or distant metastasis at presentation: Retrospective Cohort Study. Thyroid, 2023; 33(6):705–714; doi: 10.1089/thy.2023.0060
18.
BezinJ, GouverneurA, PenichonM, et al.GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care, 2023; 46(2):384–390; doi: 10.2337/dc22-1148
19.
YanL, ZhenY, LiY, et al.Five-year outcome between radiofrequency ablation vs. surgery for unilateral multifocal papillary thyroid microcarcinoma. J Clin Endocrinol Metab, 2023; doi: 10.1210/clinem/dgad360
20.
LinY, WuZR, ShiYP, et al.Radiofrequency ablation of unifocal papillary thyroid microcarcinoma with BRAF V600E mutation. J Clin Endocrinol Metab, 2023; 108(11):e1298–e1305; doi: 10.1210/clinem/dgad269
21.
SasakiT, MiyauchiA, FujishimaM, et al.Comparison of postoperative unfavorable events in patients with low-risk papillary thyroid carcinoma: Immediate surgery versus conversion surgery following active surveillance. Thyroid, 2023; 33(2):186–191; doi: 10.1089/thy.2022.0444
22.
GhosseinR, GanlyI, TuttleRM, et al.Large (>4cm) intrathyroidal encapsulated well-differentiated follicular cell-derived carcinoma without vascular invasion may have negligible risk of recurrence even when treated with lobectomy alone. Thyroid, 2023; 33(5):586–592; doi: 10.1089/thy.2023.0032
23.
XuS, HuangH, HuangY, et al.Comparison of lobectomy vs total thyroidectomy for intermediate-risk papillary thyroid carcinoma with lymph node metastasis. JAMA Surg, 2023; 158(1):73–79; doi: 10.1001/jamasurg.2022.5781
24.
GraniG, GentiliM, SicilianoF, et al.A data-driven approach to refine predictions of differentiated thyroid cancer outcomes: A Prospective Multicenter Study. J Clin Endocrinol Metab, 2023; 108(8):1921–1928; doi: 10.1210/clinem/dgad075
25.
BroseMS, RobinsonBG, ShermanSI, et al.Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer, 2022; 128(24):4203–4212; doi: 10.1002/cncr.34493
26.
BusaidyNL, KondaB, WeiL, et al.Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: Results of a randomized, phase 2, open-label multicenter trial. Thyroid, 2022; 32(10):1184–1192; doi: 10.1089/thy.2022.0115
27.
LeboulleuxS, Do CaoC, ZerdoudS, et al.A phase II redifferentiation trial with dabrafenib-trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-mutated differentiated thyroid cancer. Clin Cancer Res, 2023; 29(13):2401–2409; doi: 10.1158/1078-0432.CCR-23-0046
28.
LeboulleuxS, BenisvyD, TaiebD, et al.MERAIODE: A phase II redifferentiation trial with trametinib and (131)I in metastatic radioactive iodine refractory RAS mutated differentiated thyroid cancer. Thyroid, 2023; 33(9):1124–1129; doi: 10.1089/thy.2023.0240
29.
ZhaoX, WangJR, DaduR, et al.Surgery after BRAF-directed therapy is associated with improved survival in BRAF(V600E) mutant anaplastic thyroid cancer: A Single-Center Retrospective Cohort Study. Thyroid, 2023; 33(4):484–491; doi: 10.1089/thy.2022.0504
